http://www.birmingham.ac.uk/partners/business-services/news/index.aspx?TaxonomyKey=0/1/187/194&SyndicationType=1 Contensis: http://www.contentmanagement.co.uk http://www.birmingham.ac.uk/partners/business-services/news/items/Serascience-launches-worlds-first-point-of-care-diagnostic-device-for-multiple-myeloma-.aspx Fri, 05 Apr 2013 17:23:00 GMT http://www.birmingham.ac.uk/partners/business-services/news/items/Serascience-launches-worlds-first-point-of-care-diagnostic-device-for-multiple-myeloma-.aspx http://www.birmingham.ac.uk/partners/business-services/news/items/University-of-Birmingham-Spinout-Company-is-developing-a-novel-drug-for-the-treatment-of-Glaucoma.aspx Scientists at the University of Birmingham have received funding from the Technology Strategy Board, the UK's innovation agency, to develop a novel multi action siRNA drug with proven neuroprotective and neuroregenerative activity to treat Glaucoma. Mon, 25 Mar 2013 15:01:00 GMT http://www.birmingham.ac.uk/partners/business-services/news/items/University-of-Birmingham-Spinout-Company-is-developing-a-novel-drug-for-the-treatment-of-Glaucoma.aspx glaucoma siRNA Neuregenix Ltd http://www.birmingham.ac.uk/partners/business-services/news/items/Serascience-Ltd-shortlisted-for-Medilink-UK-Healthcare-Business-Awards-2013-.aspx Having been awarded best start-up at the 2012 Medilink West Midlands Healthcare Business Awards in December, the list of acalades for Serascience could continue to grow following the recent announcement that the company has now been shortlisted for the Medilink UK Awards. Tue, 26 Feb 2013 15:22:00 GMT http://www.birmingham.ac.uk/partners/business-services/news/items/Serascience-Ltd-shortlisted-for-Medilink-UK-Healthcare-Business-Awards-2013-.aspx Medilink Serascience medical http://www.birmingham.ac.uk/partners/business-services/news/items/University-of-Birmingham-scientists-devise-unique-stroke-assessment-tool-.aspx Scientists at the University of Birmingham have devised a unique screening instrument that provides a 'one-stop' brain function profile of patients who have suffered stroke or other neurological damage. Thu, 17 Jan 2013 12:48:00 GMT http://www.birmingham.ac.uk/partners/business-services/news/items/University-of-Birmingham-scientists-devise-unique-stroke-assessment-tool-.aspx stroke Cognitive Screen Dr Wai-Ling Bickerton http://www.birmingham.ac.uk/partners/business-services/news/items/Need-help-to-develop-an-idea.aspx The University of Birmingham is delighted to announce its new Innovation Voucher competition to help businesses develop and grow. Fri, 02 Nov 2012 14:33:00 GMT http://www.birmingham.ac.uk/partners/business-services/news/items/Need-help-to-develop-an-idea.aspx innovation Innovation Voucher University of Birmingham http://www.birmingham.ac.uk/partners/business-services/news/items/University-and-Trust-sign-up-to-historic-health-partnership-.aspx The University of Birmingham and University Hospitals Birmingham NHS Foundation Trust have today announced a groundbreaking joint working agreement to be known as Birmingham Health Partners (BHP). Thu, 01 Dec 2011 11:23:00 GMT http://www.birmingham.ac.uk/partners/business-services/news/items/University-and-Trust-sign-up-to-historic-health-partnership-.aspx Medical and Dental Sciences http://www.birmingham.ac.uk/partners/business-services/news/items/HealthBusbeginsfirstclinicalresearchstudies.aspx Mon, 14 Mar 2011 11:53:00 GMT http://www.birmingham.ac.uk/partners/business-services/news/items/HealthBusbeginsfirstclinicalresearchstudies.aspx http://www.birmingham.ac.uk/partners/business-services/news/items/native-antigen.aspx The Native Antigen Company (NAC) has been formed following a spin-out from PsiOxus, formerly Hybrid BioSystems, itself a university of Birmingham Spin-out. Tue, 25 Jan 2011 17:06:00 GMT http://www.birmingham.ac.uk/partners/business-services/news/items/native-antigen.aspx NAC native antigen company PsiOxus http://www.birmingham.ac.uk/partners/business-services/news/items/15Dec2010-vaccine-technology.aspx University of Birmingham spin-out company, Hybrid BioSystems, Ltd. (Hybrid), and Myotec Therapeutics, Ltd. (Myotec) today announced their merger to form PsiOxus Therapeutics, Ltd. (PsiOxus), a new, development stage biotechnology company using non-traditional approaches to novel therapeutics for cancer and wasting diseases. Wed, 15 Dec 2010 12:20:00 GMT http://www.birmingham.ac.uk/partners/business-services/news/items/15Dec2010-vaccine-technology.aspx Hybrid BioSystems Myotec Therapeutics Myotec therapeutics cancer wasting diseases biotechnology PsiOxus